Sunday, 20 September 2026European Markets

FOUNTAIN Stock Bullish Momentum With A 14.5% Jump Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with FOUNTAIN (FOU.BR) jumping 14.5% to €1.50 on Friday while BEL 20 slid 0.26% to €4,170.84.

About FOUNTAIN

Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in in France, Belgium, the Netherlands, and rest of European Countries. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was incorporated in 1972 and is based in Braine l'Alleud, Belgium.

Earnings Per Share

As for profitability, FOUNTAIN has a trailing twelve months EPS of €0.18.

PE Ratio

FOUNTAIN has a trailing twelve months price to earnings ratio of 8.33. Meaning, the purchaser of the share is investing €8.33 for every euro of annual earnings.

Volume

Today's last reported volume for FOUNTAIN is 5000 which is 439.37% above its average volume of 927.

More news about FOUNTAIN (FOU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com